Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00723957 · ClinicalTrials.gov registry record · Phase 2
A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung Cancer
A Phase 2 study, sponsored by R-Pharm.
- Completed
- Registry status
- Phase 2
- Development phase
- 260
- Enrollment target
NCT00723957: Completed Phase 2 study, sponsored by R-Pharm.
NCT00723957 is a Phase 2 study that has completed, run by R-Pharm. The registered enrollment target is 260 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00723957, a Phase 2 study, has completed, sponsored by R-Pharm.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 260 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether progression-free survival with ixabepilone is superior to that achieved with paclitaxel plus carboplatin in participants with advanced nonsmall-cell lung cancer and beta III (βIII)-tubulin-positive tumors.
Primary Outcome
Progression-free survival is defined as the period from date of randomization to date of disease progression or death. For participants who do not progress or die at the end of the study, progression-free survival was censored at the last tumor assessment date. For those who have no on-study tumor assessment, progression-free survival was censored at the date of randomization. A tumor was considered to be beta III (βIII)-tubulin positive if 50% or more of the tumor cells had a βIII-tubulin immun
Interventions
- DRUG Ixabepilone, 32 mg/m^2
- DRUG Paclitaxel, 200 mg/m^2
- DRUG Carboplatin (area under the concentration curve [AUC] 6)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 260 participants |
| Start Date | 2008-12 |
| Est. Completion | 2011-08 |
| Phase | Phase 2 |
What the finished NCT00723957 record still lists
NCT00723957 is an interventional study that assigns participants to a tested intervention. The registered 260 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (95% higher).
The record links to 0 conditions, and to 3 interventions - of which Ixabepilone, 32 mg/m^2 is the first listed.
NCT00723957 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00723957 about?
NCT00723957 is a clinical study titled "A Randomized Phase 2 Study of Ixabepilone Plus Carboplatin and Paclitaxel Plus Carboplatin in Advanced Nonsmall-Cell Lung Cancer". The purpose of this study is to determine whether progression-free survival with ixabepilone is superior to that achieved with paclitaxel plus carboplatin in participants with advanced nonsmall-cell lung cancer and beta III (βIII)-tubulin-positive tumors.
What is the current status of trial NCT00723957?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 260 participants. The study started on 2008-12. Estimated completion is 2011-08.
What interventions are being tested in trial NCT00723957?
The interventions under investigation include: Ixabepilone, 32 mg/m^2 (DRUG), Paclitaxel, 200 mg/m^2 (DRUG), Carboplatin (area under the concentration curve [AUC] 6) (DRUG).
Who is sponsoring clinical trial NCT00723957?
This trial is sponsored by R-Pharm, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00723957's enrollment target sits among peer trials
260 210th of 2000 higher than 1,789 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02283996 · 260 participants · Phase 4
Adhesive Capsulitis: Prospective Analysis of Efficacy and Financial Impact for Use of Physical Therapy in Treatment
- NCT03276793 · 260 participants · NA
Brain Connectivity in Depression
- NCT03407469 · 260 participants
Measurement of Adherence and Health-Related Quality of Life, and Health-Care Resource Utilization
- NCT03713125 · 260 participants · NA
Executive Function in Early Childhood
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia